{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T08:55:42Z","timestamp":1784796942739,"version":"3.55.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Serogroup B meningococcal (MenB) disease remains a serious public health concern. Recombinant protein-based vaccines have been licensed since the mid-2010s, but ongoing surveillance is needed to capture rare or long-term adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed reports submitted to the Vaccine Adverse Event Reporting System (VAERS) from 2015Q1 to 2025Q3,with data available through 30 September 2025. Cases explicitly identifying MenB vaccines were included. Events were coded with MedDRA, and disproportionality analyses were conducted using Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), and Empirical Bayes Geometric Mean (EBGM). Subgroup analyses assessed differences by age, sex, seriousness, and coadministration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 16,611 reports were identified, of which 19.9% were serious. Most events reflected expected reactogenicity such as fever, syncope, headache, and injection site reactions. Several unlabeled events, including pallor and hypotonia, showed elevated RORs. Time-to-onset analyses demonstrated clustering within 2\u00a0days of vaccination across all strata, with serious events occurring earlier than non-serious events. No novel syndromic clusters were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MenB vaccines show a favorable safety profile in real-world use. While most events align with established product information, a small number of disproportionate but unlabeled events merit continued pharmacovigilance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1745876","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:59:12Z","timestamp":1773817152000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Post-marketing safety profile of meningococcal group B vaccines: a real-world disproportionality analysis of the VAERS database, 2015Q1\u20132025Q3"],"prefix":"10.3389","volume":"17","author":[{"given":"Guojun","family":"Liang","sequence":"first","affiliation":[{"name":"Huadu District People\u2019s Hospital of Guangzhou","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Huang","sequence":"additional","affiliation":[{"name":"Huadu District People\u2019s Hospital of Guangzhou","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihui","family":"Huang","sequence":"additional","affiliation":[{"name":"Huadu District People\u2019s Hospital of Guangzhou","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Liu","sequence":"additional","affiliation":[{"name":"Huadu District People\u2019s Hospital of Guangzhou","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Song","sequence":"additional","affiliation":[{"name":"Huadu District People\u2019s Hospital of Guangzhou","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2245705","DOI":"10.1080\/21645515.2023.2245705","article-title":"Safety and immunogenicity of co-administered meningococcal serogroup B (4CMenB) vaccine: a literature review","volume":"19","author":"Abitbol","year":"2023","journal-title":"Hum. Vaccin Immunother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/0264-410x(94)00007-a","article-title":"Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide","volume":"13","author":"Bartoloni","year":"1995","journal-title":"Vaccine"},{"key":"B3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2333106","DOI":"10.1080\/21645515.2024.2333106","article-title":"Available evidence on the co-administration of the four-component meningococcal B vaccine (4CMenB) with three vaccines at the same visit among pediatric individuals","volume":"20","author":"Bonanni","year":"2024","journal-title":"Hum. Vaccin Immunother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40264-015-0289-5","article-title":"Comparison of statistical signal detection methods within and across spontaneous reporting databases","volume":"38","author":"Candore","year":"2015","journal-title":"Drug Saf."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fdsfr.2023.1323057","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems","volume":"3","author":"Cutroneo","year":"2024","journal-title":"Front. Drug Saf. Regul."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2020043","DOI":"10.1080\/21645515.2021.2020043","article-title":"Product review on the IMD serogroup B vaccine Bexsero(R)","volume":"18","author":"Deghmane","year":"2022","journal-title":"Hum. Vaccin Immunother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/HEP.0000000000000018","article-title":"Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration","volume":"77","author":"Diaz-Gonzalez","year":"2023","journal-title":"Hepatology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"ofaa516","DOI":"10.1093\/ofid\/ofaa516","article-title":"Safety surveillance of bivalent meningococcal group B vaccine, vaccine adverse event reporting system, 2014-2018","volume":"7","author":"Duffy","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1542\/peds.106.4.e52","article-title":"Hypotonic\u2013hyporesponsive episodes reported to the vaccine adverse event reporting system (VAERS), 1996\u20131998","volume":"106","author":"DuVernoy","year":"2000","journal-title":"Pediatrics"},{"key":"B11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B12","doi-asserted-by":"publisher","first-page":"S345","DOI":"10.2105\/AJPH.2008.143081","article-title":"What should an ideal vaccine postlicensure safety system be?","volume":"99","author":"Griffin","year":"2009","journal-title":"Am. J. Public Health"},{"key":"B13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00002018-200326030-00003","article-title":"Quantitative methods in pharmacovigilance: focus on signal detection","volume":"26","author":"Hauben","year":"2003","journal-title":"Drug Saf."},{"key":"B14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how's and what's of vaccine reactogenicity","volume":"4","author":"Herve","year":"2019","journal-title":"NPJ Vaccines"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1086\/522190","article-title":"Lack of association between group B meningococcal disease and autoimmune disease","volume":"45","author":"Howitz","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1007\/s40121-024-01026-w","article-title":"Understanding the sequelae of invasive meningococcal disease in the United States","volume":"13","author":"Marshall","year":"2024","journal-title":"Infect. Dis. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/cid\/civ423","article-title":"Deaths reported to the vaccine adverse event reporting System, United States, 1997-2013","volume":"61","author":"Moro","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1080\/14760584.2019.1676154","article-title":"Challenges in evaluating post-licensure vaccine safety: observations from the centers for disease control and prevention","volume":"18","author":"Moro","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"B19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40265-013-0155-7","article-title":"A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program","volume":"74","author":"O'Ryan","year":"2014","journal-title":"Drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","article-title":"Systematic review of invasive meningococcal disease: Sequelae and quality of life impact on patients and their caregivers","volume":"7","author":"Olbrich","year":"2018","journal-title":"Infect. Dis. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1056\/NEJMoa1614474","article-title":"A bivalent meningococcal B vaccine in adolescents and young adults","volume":"377","author":"Ostergaard","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.vaccine.2021.11.071","article-title":"Safety surveillance of meningococcal group B vaccine (Bexsero(R)), vaccine adverse event reporting system, 2015-2018","volume":"40","author":"Perez-Vilar","year":"2022","journal-title":"Vaccine"},{"key":"B23","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41541-021-00388-3","article-title":"Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect","volume":"6","author":"Ruiz","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1007\/s40121-024-01063-5","article-title":"Global epidemiology of meningococcal disease-causing serogroups before and after the COVID-19 pandemic: a narrative review","volume":"13","author":"Shen","year":"2024","journal-title":"Infect. Dis. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the vaccine adverse event reporting system (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"B26","doi-asserted-by":"publisher","first-page":"ofaa143","DOI":"10.1093\/ofid\/ofaa143","article-title":"Immunogenicity and reactogenicity of a reduced schedule of a 4-component capsular group B meningococcal vaccine: a randomized controlled trial in infants","volume":"7","author":"Valente","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2017.1287642","article-title":"Hypotonic-hyporesponsive episodes after administration of hexavalent DTP-based combination vaccine: a description of 12 cases","volume":"13","author":"Vigo","year":"2017","journal-title":"Hum. Vaccin Immunother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3390\/vaccines13070767","article-title":"Bioengineering outer-membrane vesicles for vaccine development: strategies, advances, and perspectives","volume":"13","author":"Zahid","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/0962280211403602","article-title":"Disproportionality methods for pharmacovigilance in longitudinal observational databases","volume":"22","author":"Zorych","year":"2013","journal-title":"Stat. Methods Med. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1745876\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:59:14Z","timestamp":1773817154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1745876\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":29,"alternative-id":["10.3389\/fphar.2026.1745876"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1745876","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"article-number":"1745876"}}